Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Practical approach to MRD testing in breast cancer: Q&A.
Journal: Clinical advances in hematology & oncology : H&O
Published: June 12, 2026
Addressing late detection of systemic relapse, the clinical blind spot.
Journal: Clinical advances in hematology & oncology : H&O
Published: June 12, 2026
Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.
Journal: Clinical advances in hematology & oncology : H&O
Published: June 12, 2026
Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.
Journal: The oncologist
Published: June 11, 2026
A phase 1 study of PF-07260437, a B7-H4 × CD3 bispecific T-cell engager, in patients with advanced or metastatic breast, ovarian, and endometrial cancer.
Journal: Investigational new drugs
Published: February 02, 2026
Editorial: Case reports in breast cancer 2023-2024.
Journal: Frontiers in oncology
Published: September 23, 2025
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Journal: Cancer research communications
Published: February 12, 2025
Inhibition of lysine acetyltransferase KAT6 in ER+HER2- metastatic breast cancer: a phase 1 trial.
Journal: Nature medicine
Published: April 23, 2024
Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series.
Journal: Frontiers in oncology
Published: April 17, 2024
Newly Approved and Emerging Agents in HER2-Positive Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: December 20, 2022
Last Updated: 09/26/2026